tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
PremiumThe FlyIntellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
1M ago
FDA appoints Richard Pazdur as Director of CDER
Premium
The Fly
FDA appoints Richard Pazdur as Director of CDER
1M ago
Intellia Therapeutics downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Intellia Therapeutics downgraded to Hold from Buy at JonesResearch
1M ago
Intellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright
PremiumThe FlyIntellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright
1M ago
Intellia Therapeutics presents Phase 1/2 data on lonvo-z
Premium
The Fly
Intellia Therapeutics presents Phase 1/2 data on lonvo-z
1M ago
Intellia Therapeutics’ Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Intellia Therapeutics’ Earnings Call: Progress Amid Challenges
1M ago
Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year
PremiumThe FlyIntellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year
1M ago
Intellia Therapeutics price target lowered to $4 from $9 at Baird
Premium
The Fly
Intellia Therapeutics price target lowered to $4 from $9 at Baird
1M ago
Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges
Premium
Ratings
Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100